Breakthrough Drug Corners “Undruggable” Pancreatic Cancer

For forty years, doctors called the gene that drives most pancreatic cancers “undruggable” — now, for the first time, drugs are hitting that target directly, and the results are turning heads across the cancer research world.

Quick Take

A mutated gene called KRAS drives roughly 90% of pancreatic cancers, and new drugs targeting it are showing real results in clinical trials for the first time.
A drug called daraxonrasib showed a median overall survival of 14.5 months in second-line pancreatic cancer patients — a meaningful number in a disease known for brutal outcomes.
Resistance to these drugs is a documented problem, and experts say combinations with immunotherapy may be the key to making results last longer.
Phase III trials are now underway, meaning the next two to three years could determine whether this approach truly changes how pancreatic cancer is treated.

The Gene That Drove Pancreatic Cancer for Decades Without a Drug to Fight It

The KRAS gene acts like a light switch inside cells. When it mutates, it gets stuck in the “on” position, telling cells to grow without stopping. ^[8] That runaway signal is what makes pancreatic cancer so aggressive. Scientists knew this for decades. The problem was that the KRAS protein’s shape made it nearly impossible for drugs to grab onto and block. Researchers called it “undruggable,” and for a long time, that label stuck.

That changed when chemists found a small pocket on the mutated KRAS protein that normal KRAS doesn’t have. That tiny groove became the foothold that drug developers needed. ^[7] The first drugs to exploit it — sotorasib and adagrasib — were approved for lung cancer and then tested in pancreatic cancer. They worked, but not as well or as long as doctors hoped. Still, the door was now open, and a new wave of more powerful drugs followed quickly behind.

What the New Drug Data Actually Shows — and What It Does Not

Daraxonrasib, also called RMC-6236, is one of the most talked-about drugs in this new wave. A phase I/Ib trial reported a median overall survival of 14.5 months and progression-free survival of 8.5 months in second-line patients with KRAS mutations. ^[1] Those numbers sound modest, but in metastatic pancreatic cancer — where median survival after diagnosis has historically been measured in months — they represent a genuine step forward. An objective response rate of 29% in the second-line group added to the early optimism.

The earlier approved drugs, sotorasib and adagrasib, showed response rates of roughly 40% and solid disease control rates in some patients. ^[2] But “disease control” and “cure” are very different things. Tumors in many patients eventually found ways around the drug. Secondary mutations and alternative growth pathways allowed cancer cells to survive and multiply again. This resistance problem is not a minor footnote — it is the central challenge that will decide whether KRAS-targeted therapy becomes a true game-changer or a promising but limited tool.

A New Strategy: Destroy the Protein Instead of Just Blocking It

Some researchers are not trying to block the mutant KRAS protein at all. They are trying to destroy it completely. A technology called Proteolysis Targeting Chimeras, or PROTACs, works by tagging the abnormal KRAS protein for disposal by the cell’s own waste-removal system. ^[4] Another drug, setidegrasib, takes a similar approach — it degrades and removes the mutant protein rather than simply blocking its activity. ^[5] The logic is straightforward: a protein that no longer exists cannot drive tumor growth or mutate to resist a drug.

Penn Medicine researchers found that adding immunotherapy to KRAS inhibitors boosted responses in early lab and animal studies. ^[3] The idea is that KRAS inhibitors can shrink tumors and make them more visible to the immune system, while immunotherapy trains that immune system to attack what remains. Neither approach alone solves the problem. Together, they may. That combination strategy is now moving into human trials, and the results over the next few years will be closely watched by oncologists worldwide.

Why Patients Should Feel Cautious Hope, Not Celebration Yet

The history of cancer research is full of drugs that looked transformative in early trials and then disappointed in larger ones. Pancreatic cancer has been especially cruel in this regard. The current KRAS data comes mostly from small, carefully selected patient groups. Most patients in these trials had a specific KRAS mutation subtype, meaning the results may not apply to everyone with the disease. Randomized phase III trials — the gold standard for proving a drug works — are still underway. ^[1] Until those results are in, honest doctors will call this promising, not proven.

That said, the science behind KRAS targeting is more solid than many previous attempts. The drugs are hitting a real, confirmed driver of the disease. Response rates are measurable. Survival numbers, while still far from where anyone wants them, are moving in the right direction. For patients and families who have watched this disease take loved ones in a matter of months, even cautious progress is worth understanding. The next two to three years of trial data will tell us whether this is the beginning of a genuine shift — or another hard lesson in how difficult pancreatic cancer truly is to beat.